Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex

被引：4
|
作者：
Giuliano, Simone [1 ]
Sbrana, Francesco [3 ]
Tascini, Carlo [1 ,2 ,3 ]
机构：
[1] Udine Univ Hosp, Infect Dis Clin, Udine, Italy
[2] Udine Univ Hosp, Dept Med Area, Udine, Italy
[3] Fdn Toscana Gabriele Monasterio, Reference Ctr Diag & Treatment Inherited Dyslipide, Lipoapheresis Unit, I-56124 Pisa, Italy
来源：
LANCET INFECTIOUS DISEASES | 2023年 / 23卷 / 08期
关键词：
IN-VITRO;
D O I：
10.1016/S1473-3099(23)00422-X
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：E274 / E274
页数：1
相关论文
共 50 条
  • [1] Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex
    Covvey, Jordan R.
    Guarascio, Anthony J.
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024,
  • [2] In vitro antibacterial activity of sulbactam-durlobactam in combination with other antimicrobial agents against Acinetobacter baumannii-calcoaceticus complex
    Mcleod, Sarah M.
    Carter, Nicole M.
    Bradford, Patricia A.
    Miller, Alita A.
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2024, 109 (03)
  • [3] In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017
    McLeod, Sarah M.
    Moussa, Samir H.
    Hackel, Meredith A.
    Miller, Alita A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (04)
  • [4] In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021
    Karlowsky, James A.
    Hackel, Meredith A.
    McLeod, Sarah M.
    Miller, Alita A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (09)
  • [5] Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK)
    Miller, Alita A.
    Moussa, Samir H.
    McLeod, Sarah M.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (05) : e0169823
  • [6] In vitro pharmacokinetics/pharmacodynamics of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complex
    O'Donnell, John
    Tanudra, Angela
    Chen, April
    Miller, Alita A.
    Mcleod, Sarah M.
    Tommasi, Ruben
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (01)
  • [7] Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections
    August, Benjamin
    Matlob, Andrew
    Kale-Pradhan, Pramodini B.
    [J]. ANNALS OF PHARMACOTHERAPY, 2024, 58 (07) : 735 - 741
  • [8] Efficacy of Sulbactam-Durlobactam (SUL-DUR) Compared to Colistin (COL) against Acinetobacter baumannii-calcoaceticus Complex (ABC) Monomicrobial and Polymicrobial Infections in a Phase 3 Trial
    不详
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2023, 10 : S1 - S1274
  • [9] In vivo dose response and efficacy of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against the Acinetobacter baumannii-calcoaceticus complex
    ODonnell, John
    Tanudra, Angela
    Chen, April
    Newman, Joseph
    McLeod, Sarah M.
    Tommasi, Ruben
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023,
  • [10] Clinical Outcomes for Patients With Monomicrobial vs Polymicrobial Acinetobacter baumannii-calcoaceticus Complex Infections Treated With Sulbactam-Durlobactam or Colistin: A Subset Analysis From a Phase 3 Clinical Trial
    McLeod, Sarah M.
    Miller, Alita A.
    Rana, Khurram
    Altarac, David
    Moussa, Samir H.
    Shapiro, Adam B.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (04):
12345